Inside the research
Johnson & Johnson
JNJ Research profile · latest available data
Price overview
$271.22
▲ +0.54 (+0.2%)
| 52w hi | $278.43 |
|---|---|
| 52w lo | $173.81 |
| Vol | 4.09M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.23
| Short | +0.16 |
|---|---|
| Medium | +0.33 |
| Long | +0.17 |
computed 2026-09-27
Key fundamentals
Johnson & Johnson
Healthcare · Drug Manufacturers - General
| Market cap | $653.61B |
|---|---|
| Enterprise value | $681.89B |
| Trailing P/E | 31.46x |
| Forward P/E | 22.34x |
| EV / EBITDA | 19.55x |
| P / S (ttm) | 6.67x |
| Profit margin | 21.5% |
| Return on equity | 25.7% |
| Revenue growth | +6.6% |
| Earnings growth | -0.9% |
| Debt / equity | 57.71 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.18 | |
| Sector | +0.08 | |
| Technical | +0.13 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Risk Metrics
| Beta vs SPX | -0.02 |
|---|---|
| Corr SPX | -0.02 |
| Annual vol | 19.1% |
| Annual ret | +26.9% |
| Sharpe | 1.41 |
| Max DD | -14.3% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $252.42 |
|---|---|
| High / Low | $285.00 / $155.00 |
| Median | $259.00 |
| Analysts | 24 |
| Strong Buy | 5 | |
|---|---|---|
| Buy | 9 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-04-15 | Wells Fargo | → Overweight |
| 2026-04-15 | Stifel | → Hold |
| 2026-04-15 | Barclays | → Equal-Weight |
| 2026-04-10 | Morgan Stanley | → Overweight |
| 2026-03-30 | RBC Capital | → Outperform |
| 2026-03-19 | Barclays | → Equal-Weight |
Officers & Board
| Director | Paula Johnson since 2023 |
|---|---|
| Director | Darius Adamczyk since 2022 |
| CEO | Joaquin Duato since 2022 |
| Director | Joaquin Duato since 2022 |
| Director | Nadja West since 2020 |
| Director | Mark Weinberger since 2019 |
| Director | Hubert Joly since 2019 |
| Director | Marillyn Hewson since 2019 |
| Director | Jennifer Doudna since 2018 |
| Director | Mary Beckerle since 2015 |
| Director | Scott Davis since 2014 |
| Director | Mark McClellan since 2013 |
| Director | Anne Mulcahy since 2009 |
| Founder | Edward Mead Johnson current |
| Founder | James Wood Johnson current |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Officer / Director Change, Exhibits | read |
| 2026-07-29 | Reg FD Disclosure, Exhibits | read |
| 2026-07-28 | Reg FD Disclosure, Exhibits | read |
| 2026-07-15 | Earnings Release, Exhibits | read |
| 2026-04-28 | Shareholder Vote, Exhibits | read |
| 2026-04-14 | Earnings Release, Other Material Event… | read |
| 2026-01-21 | Earnings Release, Exhibits | read |
| 2025-10-14 | Earnings Release, Other Material Event… | read |
| 2025-09-09 | Officer / Director Change | read |
| 2025-07-16 | Earnings Release, Exhibits | read |
| 2025-06-10 | Officer / Director Change | read |
| 2025-04-30 | Officer / Director Change, Shareholder Vote… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the B | Sell | 20.98K | $5.50M |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the B | Sell | 102.31K | $26.70M |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the B | Option exercise | 123.29K | $14.26M |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Option exercise | 9.34K | $1.23M |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 6.57K | $1.68M |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 9.34K | $2.41M |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the B | Sell | 6.52K | $1.69M |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the B | Sell | 41.96K | $10.83M |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Option exercise | 11.13K | $1.44M |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 23.05K | $5.79M |
Flow & Concentration
| Insider 180d net | -$57.01M |
|---|---|
| Insider buys / sells | 0 / 8 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 98.4% |
| HHI | 5,605 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $33.98B | 133.78M |
| Fidelity / FMR LLC | $5.74B | 22.60M |
| Capital Research / Capital World | $2.99B | 11.77M |
| Citadel Advisors | $2.13B | 8.39M |
| AQR Capital Management | $738.49M | 2.91M |
| Millennium Management | $549.64M | 2.16M |
| Bridgewater Associates | $169.94M | 669.13K |
| T. Rowe Price Group | $5.84M | 23.00M |
As of 2026-06-30
Connections
Subsidiarys: Johnson & Johnson Pharmaceutical Research and Development
Dividends
| Yield (TTM) | 0.96% |
|---|---|
| $ / share (TTM) | $2.60 |
| 5y CAGR | +5.2% |
Annual dividend per share
| 2021 | $4.19 |
|---|---|
| 2022 | $4.45 |
| 2023 | $4.70 |
| 2024 | $4.91 |
| 2025 | $5.14 |
| 2026 | $1.30 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $1.38M | Department of Veterans Affairs | DRY CHEMISTRY/IMMUNOCHEMISTRY SYSTEM |
| $1.36M | Department of Defense | CHEMISTRY ANALYZER |
| $1.26M | Department of Veterans Affairs | CHEMISTRY |
| $982.69K | Department of Defense | CHEMISTRY ANALYZER |
| $891.05K | Department of Defense | 4569174801!2.7MM/3.5MM VA-LCP ANKLE |
| $868.52K | Department of Defense | IMMUNOASSAY TESTING |
| $745.32K | Department of Defense | 4569301060!2.7MM/3.5MM VA-LCP ELBOW |
| $633.80K | Department of Defense | COST PER REPORTABLE VITROS 5600 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $94.19B | +2.7% | |
| Gross profit | $63.94B | +2.5% | |
| Operating income | $21.59B | +6.8% | |
| Net income | $26.80B | +19.1% | |
| Cash from ops | $22.79B | +2.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $271.70 | $272.25 | $269.26 | $271.22 | 4.09M |
| Sep 24 | $269.52 | $275.23 | $269.01 | $270.68 | 6.32M |
| Sep 23 | $269.47 | $272.14 | $266.50 | $269.17 | 6.63M |
| Sep 22 | $267.51 | $270.10 | $265.04 | $269.19 | 5.68M |
| Sep 21 | $271.74 | $273.73 | $268.50 | $269.47 | 4.49M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →